Role of Coagulation, Inflammation and Vessels in Chronic Liver Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Chronic liver diseases represent a major public health problem and are responsible for more than 150,000 deaths in Europe each year. These diseases are accompanied by symptoms that profoundly alter the quality of life and mainly affect people of working age, leading to a major economic impact.

Coagulation disorders, inflammation and vascular alterations are associated with chronic liver diseases but their role in the onset and/or progression of liver diseases is still not fully understood.

A better understanding of chronic liver diseases and in particular of the factors that play a role in the onset and progression of these diseases would improve patient management and therefore have a positive impact on individuals, but also on the healthcare system and the economy.

Eligibility criteria

Qualifiers

Liver biopsy showing chronic liver disease or cirrhosis

Liver elastography by Fibroscan® assessing the elasticity of the liver at more than 10 kpa

Combination of clinical, biological and imaging criteria characteristic of chronic liver disease (signs of portal hypertension, liver failure and liver dysmorphia in a patient with at least one risk factor for chronic liver disease)

Disqualifiers

Pregnant or lactating women

Protected populations: persons under guardianship, under curatorship or safeguard of justice

Patient under AME

Patient who has not signed a consent form

Trial design

Treatments tested in this trial

  • biomarker assay

Treatment groups

360 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Locations

1
Beaujon Hospital Clichy France

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor